Evaxion's EVX-01 shows durable clinical outcomes in three-year phase 2 melanoma data

• Evaxion reported three-year Phase 2 data for personalized cancer vaccine EVX-01 showing durable clinical outcomes and immune system activation in advanced melanoma patients.
• Results were presented last week at the European Society for Medical Oncology Congress in Madrid, according to the October 30, 2026, announcement.
• EVX-01 is the most advanced drug candidate developed using its AI-Immunology platform, which received the 2026 International Prix Galien best digital health solution award.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006992), on October 30, 2026, and is solely responsible for the information contained therein.